LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
LumiraDx submits a traditional 510 Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx...
City Of United Kingdom United States Carol Adiletto Francis Drug Administration Lumiradx Limited Nasdaq
Source: marketscreener.com